Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences, in collaboration ...

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

At Martha’s Vineyard, Touch Talks Wellness and BlackDoctor.org joined forces to host an urgent and deeply personal conversation on cancer disparities in the Black community. Powered by partnerships ...

We write as members of the international medical community to call upon the Israeli Medical Association (IMA) to uphold its commitment to ethical principles by supporting independent international ...

Detailed price information for Tyra Biosciences Inc (TYRA-Q) from The Globe and Mail including charting and trades.

Orman also has spotted some stock-market winners. On CNBC's "Fast Money" in late October 2023, she recommended Palantir Technologies (PLTR), Microsoft (MSFT), Amazon.com (AMZN), Shopify (SHOP) and ...

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not ...

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

BlackDoctor.org gathered a powerful panel of survivors, advocates, clinicians, and pharma leaders in Washington, D.C. for a ...

Earl Davis, Head of Fixed Income and Money Markets at BMO Global Asset Management, joins BNN Bloomberg to discuss expectations from U.S. FED chair's speech.

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.